Asset

ZILGANERSEN

Ionis Pharmaceuticals Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (1)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT04849741phase3active_not_recruiting2021-06-012025-08-22Ionis Pharmaceuticals, Inc.A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)

FDA applications (1)

ApplicationTypeApplicant
NDA 220210NDAIONIS PHARMS INC

Marketed products (1)

  • ZANVASTRO